VEGFA and neoplasm: The observation that the anti-VEGF agent bevacizumab provides survival benefits only when given with chemotherapy [10,11], and that patients whose tumor hypoxia decreased following treatment with anti-angiogenic treatments survive longer lead to a novel hypothesis on how anti-angiogenic drugs function.